| abstract |
The invention generally provides a novel labeling strategy using compounds that are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is. a disease cell cycle target compound, a tumor angiogenesis target ligand, a tumor apoptosis target ligand, a disease receptor target ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD2, monoclonal antibody CD31, monoclonal antibody CD31, monoclonal antibody , luteinizing hormone, pyridoxal, quinazoline, thalidomide, transferdn or trimethyllysine. The present invention also relates to sets employing the present compounds, as well as to methods for assessing the pharmacology of a particular agent using the present compounds. |